ArticleRevista de la Facultad de Ciencias Medicas (Cordoba, Argentina)2026
Steroid-Refractory Cutaneous Graft-versus-Host Disease: a Case Report
Article in Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous graft-versus-host disease (cGVHD) is a potentially severe complication following allogeneic hematopoietic stem cell transplantation. We present the case of a 40-year-old woman with acute myeloid leukemia who underwent an allogeneic transplant with an HLA-matched unrelated donor. During the post-transplant phase, she developed steroid-refractory cutaneous GVHD, progressing to widespread lesions compatible with toxic epidermal necrolysis (NET-like). Management included second- and third-line therapies, such as JAK inhibitors (ruxolitinib), immunoglobulin, biological agents (infliximab, rituximab), and extracorporeal procedures (photopheresis and plasmapheresis). Early intervention and coordination by a multidisciplinary team allowed disease control and progressive improvement of the lesions. This case emphasizes the importance of early recognition of severe cutaneous GVHD, tailoring treatment according to disease severity and clinical response, and the need for a multidisciplinary approach to reduce morbidity and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.